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Background
Prostaglandin E2 plays a crucial role in inflammation,
including pain, fever and tumorigenesis. Inflammatory
cells, fibroblasts and epithelium are the main source of
PGE2 throughout an immune response. There are four
known receptors for PGE2, E type prostanoid receptors
1–4 (EP1,2,3,4). According to recent reports, the EP4
receptor seems to be a potential target of therapeutic
treatment for attenuating inflammation as well as
increased endothelial permeability.
Methods
Primary human microvascular endothelial cells of the
lung (HMVEC-L) were cultured and transfected using
siRNA approach. The mRNA level of the EP4 receptor
was determined using RT-PCR. EP4 receptor protein
expression was evaluated via Western blotting and flow
cytometry. Changes in electrical impedance were mea-
sured using an ECIS application. Morphological altera-
tions were observed via immunofluorescent staining of
b-catenin and F-actin. Cell cycle and apoptosis analysis
were performed using flow cytometry.
Results
The pulmonary microvascular endothelial cells express
the PGE2 receptor EP4, which was shown by flow cyto-
metry and Western blotting. In endothelial cells, EP4
receptor protein expression was down-regulated to less
than 40% by using the siRNA transfection approach.
Also, the mRNA level of the EP4 receptor was signifi-
cantly down-regulated below 15% using siRNA transfec-
tion. In the endothelial impedance measurements, the
EP4 agonist and PGE2-induced barrier enhancement was
significantly suppressed in EP4 receptor-silenced cells.
Morphological studies revealed that the thrombin-
induced disruption of endothelial monolayers could be
reversed by stimulation of EP4 receptors. Cell-cell con-
tacts were enhanced and stress fibre formation was pre-
vented by pre-treatment with PGE2 and an EP4-selective
agonist. PGE2 and the EP4 agonist did not induce any
changes in the endothelial cell cycle; however, EP4
receptor activation appeared to be protective against
staurosporine-induced apoptosis. Apoptotic cells were
determined in the sub-G1 phase of the cell cycle.
Conclusions
These data suggest EP4 receptor agonists as potential
therapeutic intervention for diseases with increased vas-
cular permeability such as acute lung injury.
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